{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:30:06Z","timestamp":1794479406008,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021372","name":"Hector Stiftung","doi-asserted-by":"publisher","award":["M 2419"],"award-info":[{"award-number":["M 2419"]}],"id":[{"id":"10.13039\/501100021372","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004426","name":"Dr Werner Jackst\u00e4dt Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005677","name":"German Jos\u00e9 Carreras Foundation for Leucemia","doi-asserted-by":"publisher","award":["DJCLS 09 R\/204"],"award-info":[{"award-number":["DJCLS 09 R\/204"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["KR2291\/12\\u20132"],"award-info":[{"award-number":["KR2291\/12\\u20132"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopha.2026.119433","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:43:39Z","timestamp":1778269419000},"page":"119433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dual inhibition of PP2A and WEE1 induces apoptosis and mitotic catastrophe in cancer cells"],"prefix":"10.1016","volume":"199","author":[{"given":"Al-Hassan M.","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Kreissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2501-8149","authenticated-orcid":false,"given":"Yanira","family":"Zeyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5027-6804","authenticated-orcid":false,"given":"Yesim Melisa","family":"G\u00fcrb\u00fczoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6798-7629","authenticated-orcid":false,"given":"Stefan","family":"Stoldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus P.","family":"Radsak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-6212","authenticated-orcid":false,"given":"Walburgis","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linping","family":"Chen-Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-045X","authenticated-orcid":false,"given":"Oliver H.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119433_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119433_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.tibs.2023.04.004","article-title":"Substrate and phosphorylation site selection by phosphoprotein phosphatases","volume":"48","author":"Nguyen","year":"2023","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.biopha.2026.119433_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188453","article-title":"The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation","volume":"1874","author":"Dzulko","year":"2020","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2026.119433_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102656","article-title":"Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules","volume":"298","author":"Haanen","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119433_bib5","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.20892\/j.issn.2095-3941.2022.0330","article-title":"Targeting PP2A for cancer therapeutic modulation","volume":"19","author":"Ronk","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biopha.2026.119433_bib6","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1158\/2159-8290.CD-23-0216","article-title":"Paradoxical activation of oncogenic signaling as a cancer treatment strategy","volume":"14","author":"Dias","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119433_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbamcr.2018.07.010","article-title":"Physiologic functions of PP2A: lessons from genetically modified mice","volume":"1866","author":"Reynhout","year":"2019","journal-title":"Biochimica Et Biophysica Acta (BBA)-Molecular Cell Research"},{"key":"10.1016\/j.biopha.2026.119433_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1101\/gad.333864.119","article-title":"Targeted chemotherapy overcomes drug resistance in melanoma","volume":"34","author":"Yue","year":"2020","journal-title":"Genes Dev."},{"key":"10.1016\/j.biopha.2026.119433_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12964-024-01597-8","article-title":"The protein phosphatase-2A subunit PR130 is involved in the formation of cytotoxic protein aggregates in pancreatic ductal adenocarcinoma cells","volume":"22","author":"Nguyen","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.biopha.2026.119433_bib10","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1158\/1078-0432.CCR-16-2299","article-title":"Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in Patients with Relapsed Solid Tumors: an open-label, dose escalation, first-in-human, phase i trial","volume":"23","author":"Chung","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119433_bib11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.20892\/j.issn.2095-3941.2022.0330","article-title":"Targeting PP2A for cancer therapeutic modulation","volume":"19","author":"Ronk","year":"2022","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.biopha.2026.119433_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","article-title":"A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target","volume":"13","author":"Ghelli Luserna di Rora","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119433_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tig.2013.02.003","article-title":"WEE1 tyrosine kinase, a novel epigenetic modifier","volume":"29","author":"Mahajan","year":"2013","journal-title":"Trends Genet"},{"key":"10.1016\/j.biopha.2026.119433_bib14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.trecan.2021.06.002","article-title":"Targeting the replication stress response through synthetic lethal strategies in cancer medicine","volume":"7","author":"Ngoi","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2026.119433_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 inhibitor: clinical development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119433_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104233","article-title":"Adavosertib and beyond: biomarkers, drug combination and toxicity of WEE1 inhibitors","volume":"193","author":"Zhang","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119433_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117076","article-title":"Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells","volume":"177","author":"Hieber","year":"2024","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119433_bib18","doi-asserted-by":"crossref","first-page":"26267","DOI":"10.1074\/jbc.R111.252569","article-title":"KAP1 protein: an enigmatic master regulator of the genome","volume":"286","author":"Iyengar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119433_bib19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-018-03096-0","article-title":"HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130","volume":"9","author":"G\u00f6der","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119433_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102520","article-title":"Class 1 histone deacetylases and ataxia-telangiectasia mutated kinase control the survival of murine pancreatic cancer cells upon dNTP depletion","volume":"10","author":"Nguyen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2026.119433_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/bs.mcb.2018.03.040","article-title":"Dissecting the role of the tubulin code in mitosis","volume":"144","author":"Ferreira","year":"2018","journal-title":"Methods Cell Biol."},{"key":"10.1016\/j.biopha.2026.119433_bib22","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1158\/1078-0432.CCR-18-0290","article-title":"Curation of the pancreatic ductal adenocarcinoma subset of the cancer genome atlas is essential for accurate conclusions about survival-related molecular mechanisms","volume":"24","author":"Peran","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119433_bib23","doi-asserted-by":"crossref","first-page":"20196","DOI":"10.1021\/acsomega.3c01558","article-title":"Synthetic and medicinal chemistry approaches toward WEE1 kinase inhibitors and its degraders","volume":"8","author":"Alli","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119433_bib24","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1021\/acschembio.1c00693","article-title":"Modulation of phosphoprotein activity by phosphorylation targeting chimeras (PhosTACs)","volume":"16","author":"Chen","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119433_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/146282","article-title":"Targeting the mitotic catastrophe signaling pathway in cancer","volume":"2015","author":"Mc Gee","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2026.119433_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/1061186X.2020.1818760","article-title":"Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications","volume":"29","author":"Shakeel","year":"2021","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2026.119433_bib27","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","article-title":"Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes","volume":"554","author":"Mueller","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119433_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/1878-0261.13638","article-title":"Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells","author":"Kansy","year":"2024","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.biopha.2026.119433_bib29","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/s41375-023-02036-2","article-title":"Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3","volume":"37","author":"Zeyn","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2026.119433_bib30","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2026.119433_bib31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13104-021-05445-7","article-title":"Drug synergy scoring using minimal dose response matrices","volume":"14","author":"Makela","year":"2021","journal-title":"BMC Res. Notes"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226004695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:46:03Z","timestamp":1794476763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226004695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S0753332226004695"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119433","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual inhibition of PP2A and WEE1 induces apoptosis and mitotic catastrophe in cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119433","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119433"}}